{"id":"W3214037196","doi":"10.1182/blood-2021-146043","title":"Safety and Preliminary Efficacy from the Expansion Cohort of a Phase 1/2 Study of Venetoclax Plus Daratumumab and Dexamethasone Vs Daratumumab Plus Bortezomib and Dexamethasone in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Medicine; Internal medicine; Dexamethasone; Venetoclax; Oncology; Multiple myeloma; Bortezomib; Lenalidomide; Proteasome inhibitor; Phases of clinical research; Gastroenterology; Clinical trial; Surgery; Leukemia; Chronic lymphocytic leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003007022,0.001034043,0.001236444,0.0003122507,0.000633365,0.0009492094,0.0006502077,0.0008635243,0.003265405],"category_scores_gemma":[0.001536298,0.0004615826,0.001706099,0.0004343679,0.000827581,0.0006657207,0.0004949018,0.003063874,0.0006735425],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001007865,"about_ca_system_score_gemma":0.001508289,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001242408,"about_ca_topic_score_gemma":0.002000312,"domain_scores_codex":[0.9990532,0.000531978,0.00004666036,0.0001423072,0.00009198731,0.0001339525],"domain_scores_gemma":[0.9985256,0.0002725541,0.0002306421,0.0002080457,0.0001237952,0.0006394205],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7758096,0.07442767,0.03311745,0.0003120376,0.001766856,0.0003816298,0.0004213616,0.002220735,0.03428211,0.0002042423,0.00381557,0.07324066],"study_design_scores_gemma":[0.2874688,0.6402142,0.05980827,0.00003185841,0.001214488,0.0006027775,0.0001048894,0.001218248,0.00560819,0.0002601757,0.003419378,0.00004871417],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9953172,0.0006296575,0.0003199042,0.0001615235,0.00004311982,0.001202449,0.001335012,0.00003011681,0.0009610227],"genre_scores_gemma":[0.9919594,0.0004288217,0.001082021,0.0003748534,0.0001112256,0.001173974,0.003598562,0.00001496434,0.001256096],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003265405,"threshold_uncertainty_score":0.01590288,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01562707189764227,"score_gpt":0.2751902275420617,"score_spread":0.2595631556444195,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}